| Literature DB >> 30738437 |
Joseph Nelson Siewe Fodjo1, Marieke C J Dekker2,3, Richard Idro4, Michel Ndahura Mandro5,6, Pierre-Marie Preux7, Alfred K Njamnshi8,9, Robert Colebunders5.
Abstract
BACKGROUND: Onchocerciasis-endemic regions are known to have a high epilepsy prevalence. Limited resources in these areas and poor access to healthcare by persons with epilepsy (PWE) result in a wide anti-epileptic treatment gap, poor seizure control and a high burden of seizure-related complications. Recent community-based surveys highlight the need for epilepsy management strategies suitable for remote onchocerciasis-endemic villages to ensure better health outcomes for PWE. In this paper, we propose a feasible approach to manage PWE in such settings. MAIN TEXT: Improved management of PWE in onchocerciasis-endemic areas may be achieved by decentralizing epilepsy care. Simplified approaches for the diagnosis and treatment of epilepsy may be used by non-physicians, under the supervision of physicians or specialists. To reduce the treatment gap, a regular supply of subsidized anti-epileptic drugs (AED) appropriate for different types of onchocerciasis-associated epilepsy should be instituted. Setting up a community-based epilepsy surveillance system will enable early diagnosis and treatment of PWE thereby preventing complications. Community awareness programs on epilepsy must be implemented to reduce stigma and facilitate the social rehabilitation of PWE. Finally, strengthening onchocerciasis elimination programs by optimizing community-directed treatment with ivermectin (CDTI) and considering alternative treatment strategies might reduce the incidence of epilepsy.Entities:
Keywords: Community-based approach; Comprehensive management; Epilepsy; Onchocerciasis
Mesh:
Year: 2019 PMID: 30738437 PMCID: PMC6368958 DOI: 10.1186/s40249-019-0523-y
Source DB: PubMed Journal: Infect Dis Poverty ISSN: 2049-9957 Impact factor: 4.520
Fig. 1Map showing onchocerciasis endemic areas. The dots indicate countries where different forms of OAE have been reported [13, 18]
Adaptation of the epilepsy screening questions to the local context
| Questions in scientific language [ | Questions explained and adapted to the context | Remark |
|---|---|---|
| 1. Loss of consciousness and/or micturition and/or drooling? | Does the person suddenly fall for a short period of time (few seconds to minutes)? During such falls, is there saliva (foam) on the mouth and/or urine on the victim? | - Sudden fall implies that the victim has no time to hold onto a support before falling. |
| 2. Absences or sudden lapse of consciousness for a short duration? | Does the person suddenly stop talking/eating/working for a short period of time (few seconds), and does not respond when you call him/her? After that, does she/he resume to what she/he was doing? | - Questions must relate to common activities such as farming, talking and eating because it is the easiest way to notice abnormal events. |
| 3. Jerky or uncontrolled movements of one or more limbs (convulsions), of sudden onset and lasting for a few minutes? | Does the person get sudden shaking of the whole body or just part of the body (hands, legs) and this then calms down after a short while? | Generalized tonic-clonic seizures are easily recognized and may have a local appellation. It could be helpful to ask the interviewee to mimic the abnormal movements. Ask also whether the person experiences isolated movements of the head (nodding seizures). Importantly, do not suggest answers. |
| 4. Sudden onset of brief body sensations, hallucinations or illusions be they visual, auditory or olfactory? | While fully awake, does the person often complain of abnormal body sensations, or seeing/ hearing/ smelling things that are not really there for a short period (few seconds to minutes)? | Non-motor seizures are difficult to explain. The best approach is to create a scenario of visual or auditory hallucinations (seeing people who are not present, hearing voices). In some cases, the symptom is well known but had never been attributed to epilepsy. Use the local word for hallucinations when screening, if it exists. |
| 5. Had it been said before that the subject had epilepsy or had presented epileptic seizures? | Ask the question using the local word for persons with epilepsy in that community. | Most families will readily answer this question. However, more tact is needed to pull out cases that are generally hidden by the family because of associated stigma [ |
Fig. 2A simplified approach to the differential diagnoses of epilepsy
Description of common first-line AED in resource-limited settings
| Drug | Indication and frequency of use | Required dosage | Remark | |
|---|---|---|---|---|
| Children | Adults | |||
| Phenobarbital | Recommended by WHO as first line AED for most seizure types, except absences; cheap and readily available [ | Given once/twice daily | Given once daily | Steady state reached after 14–21 days. Possible side effects: Drowsiness, skin rash, lethargy and hyperactivity in children, hepatic failure, Stevens Johnson syndrome |
| Carbamazepine | Indicated for focal seizures, and could be used in generalized convulsive seizures [ | Given twice daily | Given twice daily | Steady state reached in 8 days. Possible side effects: allergic skin reactions, bone marrow suppression with long-term use, blurred vision, diplopia, ataxia, nausea. Contraindicated in absences and myoclonus [ |
| Phenytoin | Indicated for treating some generalized seizures and status epilepticus [ | Given once/twice daily | Given once or twice daily | Possible side effects: drowsiness, ataxia, slurred speech, motor twitching and mental confusion, coarsening of facial features, hepatitis, gum hyperplasia, hirsutism, skin reaction including Stevens Johnson syndrome |
| Valproate | A broad spectrum anticonvulsant that can be used for both focal and generalized onset seizures. Specifically indicated for absence, atonic and myoclonic seizures [ | Given twice daily | Given twice daily | Possible side effects: sedation, tremor, transient hair loss, increase in body weight, impaired hepatic function. Use in women of childbearing age is discouraged |
Fig. 3Relationship between different actors in the epilepsy program
Constraints in implementing a community-based epilepsy program
| Aspect | Possible constraint | Proposed solution |
|---|---|---|
| Decentralizing epilepsy care | Shortages in AED availability | Advocacy to prioritize onchocerciasis |
| Remote communities very far from health centres | Institute regular mobile clinics during which the nurse reaches out to remote communities. Can be coupled with other public health activities such as immunization, and maternal & child health services. AED could be transported monthly from the clinic to the village by the CHW. | |
| Community awareness programs | Resistance by certain institutions (schools, churches, jobsites) to provide a platform for sensitization | Education of stakeholders about the importance of epilepsy sensitization in their respective institutions |
| Difficulty in conveying the message in a contextual and convincing manner | Qualitative research could identify root problems and how to best address them | |
| Evaluation and monitoring | Lack of qualified persons | Use simple reporting forms (see Additional file |
| Epilepsy-related events not reported in some health systems. | Propose an epilepsy reporting form to be used in health structures in onchocerciasis | |
| Strengthening onchocerciasis elimination programs | Insufficient public funds for bi-annual CDTI or alternative strategies | Advocacy to stakeholders about the importance of onchocerciasis elimination; make use of unpaid village volunteers for CDTI. |
| Sub-optimal ivermectin intake by the population | Sensitization of the population about the importance of ivermectin to prevent epilepsy; better timing of distribution campaigns (avoid periods of intensive farming activity with high probability of meeting empty houses during distribution) | |
| Sustainability of the program | Possibility of the program being closed after sometime due to lack of interest and/or resources | - Advocacy for stakeholders to include epilepsy programs among priority interventions in onchocerciasis-endemic regions |
| Administrative bottlenecks and corruption | - Involve high ranking local elites who value the village and the populations |
CDTI Community-directed treatment with ivermectin, AED Anti-epileptic drugs, CHW Community health workers
Research priorities on epilepsy management in onchocerciasis-endemic regions
| Aspect | Research question | Possible research direction |
|---|---|---|
| Epilepsy screening | What is the optimal screening tool to detect PWE by non-physicians? | - Need to validate screening questionnaires in different settings |
| Diagnosis of epilepsy | What is the risk of seizure recurrence in an | Prospective study to follow up healthy children in highly endemic onchocerciasis settings. If recurrence risk is found to be ≥60%, then one seizure in the presence of onchocerciasis would be considered as epilepsy [ |
| How can OAE be predicted or diagnosed in an early phase? | Prospective study in onchocerciasis-exposed children with regular clinical, electrophysiological and brain imaging assessment; evaluation of biomarkers in blood, CSF, and/or skin snips | |
| Epilepsy treatment | What is the optimal training module for first line healthcare workers to care for PWE? | Intervention study to test different training modules for epilepsy care |
| What is the optimal anti-epileptic treatment for each type of OAE, including absences and nodding seizures? | Multi-center cohort study and if possible clinical trials to evaluate the efficacy and safety of different treatment regimens | |
| Is anti-onchocerciasis treatment able to reduce the frequency of seizures in persons with OAE? | Clinical trials to assess the effect of ivermectin [ | |
| Strengthening onchocerciasis elimination programs | Is it safe to give ivermectin to children < 5 years with onchocerciasis and possibly OAE? | - Clinical trials to obtain safety data about ivermectin use in children < 5 years [ |
| Sustainability of the epilepsy care program | What is the impact and cost-effectiveness of a community-based epilepsy program? | Impact and cost analysis studies before and after the implementation of an epilepsy care program [ |
CSF Cerebrospinal fluid, PWE Person with epilepsy